Kura Oncology, Inc. (NASDAQ:KURA) was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating in a report issued on Friday.

Several other equities research analysts have also weighed in on the company. Zacks Investment Research raised Kura Oncology from a “hold” rating to a “buy” rating and set a $10.00 price objective for the company in a research note on Thursday, May 18th. Cann reissued a “buy” rating and set a $16.00 price objective on shares of Kura Oncology in a research note on Monday, May 15th. Oppenheimer Holdings, Inc. set a $16.00 price objective on Kura Oncology and gave the stock a “buy” rating in a research note on Wednesday, June 14th. Citigroup Inc. set a $13.00 target price on Kura Oncology and gave the stock a “buy” rating in a research report on Tuesday, August 8th. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $18.00 target price (up previously from $16.00) on shares of Kura Oncology in a research report on Thursday, August 10th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $14.15.

Kura Oncology (KURA) traded down 1.39% during mid-day trading on Friday, hitting $7.10. The company had a trading volume of 150,546 shares. The stock’s 50 day moving average price is $8.14 and its 200 day moving average price is $8.67. Kura Oncology has a 52-week low of $4.00 and a 52-week high of $12.10. The firm’s market cap is $196.58 million.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Monday, August 7th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.03. On average, equities research analysts predict that Kura Oncology will post ($1.60) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This story was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.thecerbatgem.com/2017/09/03/kura-oncology-inc-kura-rating-lowered-to-sell-at-valuengine.html.

Several hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC raised its holdings in shares of Kura Oncology by 25.4% during the fourth quarter. Renaissance Technologies LLC now owns 30,600 shares of the company’s stock worth $181,000 after acquiring an additional 6,200 shares in the last quarter. Nationwide Fund Advisors purchased a new stake in shares of Kura Oncology during the first quarter worth $136,000. Alethea Capital Management LLC raised its holdings in shares of Kura Oncology by 31.8% during the first quarter. Alethea Capital Management LLC now owns 84,769 shares of the company’s stock worth $746,000 after acquiring an additional 20,469 shares in the last quarter. Segantii Capital Management Ltd purchased a new stake in shares of Kura Oncology during the first quarter worth $120,000. Finally, Morgan Stanley raised its holdings in shares of Kura Oncology by 175.5% during the first quarter. Morgan Stanley now owns 430,428 shares of the company’s stock worth $3,788,000 after acquiring an additional 274,166 shares in the last quarter. Institutional investors and hedge funds own 39.07% of the company’s stock.

About Kura Oncology

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Receive News & Stock Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related stocks with our FREE daily email newsletter.